-
公开(公告)号：WO1998022500A2
公开(公告)日：1998-05-28
申请号：PCT/US1997022422
申请日：1997-11-21
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , JENKINS, Alison, L. , PHILLIPS, David, R.
IPC: C07K14/405
CPC classification number: C07K14/70546 , A61K38/00 , C07K14/70557
Abstract: The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins, particularly the phosphorylated cytoplasmic domains of the beta -subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin, methods of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.
Abstract translation: 本发明描述了肌球蛋白和膜蛋白的细胞质结构域之间的直接相互作用，特别是整联蛋白β亚单位的磷酸化胞质结构域。 本发明提供鉴定阻断整合素与肌球蛋白结合的试剂的方法，使用阻断整合素结合肌球蛋白以调节生物学和病理学过程的试剂的方法，以及提供阻断整合素介导的结合肌球蛋白从而调节相关细胞或细胞成分运动的试剂 。
-
公开(公告)号：WO1995002054A2
公开(公告)日：1995-01-19
申请号：PCT/US1994007644
申请日：1994-07-07
Applicant: COR THERAPEUTICS, INC.
IPC: C12N15/12
CPC classification number: C07K14/705 , A61K38/00
Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.
Abstract translation: 本发明涉及糖蛋白v基因。 具体地，本发明公开了糖蛋白v基因的序列和结构以及糖蛋白v多肽的氨基酸序列。 此外，描述了糖蛋白v基因与其他糖蛋白的进化关系，并显示了分离的糖蛋白v基因的几种用途。
-
公开(公告)号：WO1990000178A1
公开(公告)日：1990-01-11
申请号：PCT/US1989002893
申请日：1989-06-30
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , CHARO, Israel, F. , FITZGERALD, Laurence, A. , PHILLIPS, David, R.
IPC: C07K07/08
CPC classification number: C07K14/70557 , A61K38/00 , C07K2319/00 , C07K2319/33 , Y10S530/806
Abstract: Methods and compositions are provided for treating platelet-associated ischemic syndromes utilizing oligopeptides corresponding to regions of the platelet GPIIIa protein. The oligopeptides can be used to block platelet aggregation for numerous applications, and can serve in immunogen to raise receptor-specific antibodies.
Abstract translation: 提供了使用对应于血小板GPIIIa蛋白的区域的寡肽来治疗血小板相关缺血综合征的方法和组合物。 寡肽可用于阻断多种应用的血小板聚集，并可用于免疫原以产生受体特异性抗体。
-
4.发明申请IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION 审中-公开Bap-1的鉴定，蛋白质在蛋白质整合和参与整合信号转导中的作用
公开(公告)号：WO1998022583A1
公开(公告)日：1998-05-28
申请号：PCT/US1997020951
申请日：1997-11-18
Applicant: COR THERAPEUTICS, INC.
Inventor： COR THERAPEUTICS, INC. , LI, Shengfeng , PHILLIPS, David, R.
IPC: C12N15/12
Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to beta 3 integrins, alpha IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.
Abstract translation: 本发明提供了结合β3整联蛋白，αIIb和Src激酶并参与整联蛋白介导的信号传导的蛋白质的氨基酸和核苷酸序列。 基于该公开内容，本发明提供了用于鉴定阻断整联蛋白介导的信号传导的试剂的方法，使用阻断整联蛋白介导的信号传导调节生物和病理过程的试剂的方法以及阻断整合素介导的信号传导的试剂。
-
公开(公告)号：EP1071751A1
公开(公告)日：2001-01-31
申请号：EP99918586.1
申请日：1999-04-15
Applicant: COR THERAPEUTICS, INC.
Inventor： LAW, Deborah, Ann , PHILLIPS, David, R.
IPC: C12N5/10 , A01K67/027 , C07K14/705 , A61K49/00
CPC classification number: C12N15/8509 , A01K67/0275 , A01K2217/072 , A01K2227/105 , A01K2267/03 , C07K14/70557 , C12N2800/30
Abstract: The present invention relates to mammals into which foreign DNA has been introduced or in which various modifications or substitutions have been made to an integrin β subunit, thereby generating transgenic or genetically-engineered non-human mammals. In particular, the present invention provides a transgenic mammal in which the endogenous GP IIIa gene has been replaced with an altered or mutant GP IIIa gene in which one or all of the phosphorylatable cytoplasmic tyrosine residues have been replaced with non-tyrosine residues such as phenylalanine. Since the platelets in the blood of the resultant transgenic mammals expressing the altered or mutant GP IIIa cannot undergo tyrosine phosphorylation to the extent that it occurs in wild-type mammals, these genetically-engineered animals provide a critical tool for assessing the importance of the phosphorylation reaction for platelet function. The invention is also useful for studying the effect of the mutant GP IIIa integrin subunit on biological processes other than platelet formation.
-
Patent Agency Ranking
公开(公告)号：EP0942931A2
公开(公告)日：1999-09-22
申请号：EP97952309.0
申请日：1997-11-21
Applicant: COR THERAPEUTICS, INC.
Inventor： JENKINS, Alison, L. , PHILLIPS, David, R.
CPC classification number: C07K14/70546 , A61K38/00 , C07K14/70557
Abstract: The present invention describes a direct interaction between myosin and the cytoplasmic domain of membrane proteins, particularly the phosphorylated cytoplasmic domains of the β-subunit of integrins. The invention provides methods of identifying agents which block integrin binding to myosin, methods of using agents which block integrin binding to myosin to modulate biological and pathological processes, and provides agents that block integrin mediated binding to myosin and thereby modulate related cellular or cellular component movement.
-
7.发明公开IDENTIFICATION OF Bap-1, A PROTEIN THAT BINDS TO INTEGRIN AND IS INVOLVED IN INTEGRIN-MEDIATED SIGNAL TRANSDUCTION 失效IDENTIFYING BAP-1，即整关系和整合素介导SIGNALUEBERTRAGUNG涉及到蛋白质
公开(公告)号：EP0939815A1
公开(公告)日：1999-09-08
申请号：EP97949458.0
申请日：1997-11-18
Applicant: COR THERAPEUTICS, INC.
Inventor： LI, Shengfeng , PHILLIPS, David, R.
IPC: G01N33 , A61K45 , A61P7 , A61P29 , A61P35 , C07K14 , C07K16 , C07K17 , C12N1 , C12N5 , C12N15 , C12P21 , C12Q1 , A61K38
Abstract: The present invention provides the amino acid and nucleotide sequence of a protein that binds to β3 integrins, αIIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block integrin mediated signaling, methods of using agents that block integrin mediated signaling to modulate biological and pathological processes, and agents that block integrin mediated signaling.
-
公开(公告)号：EP1102840A2
公开(公告)日：2001-05-30
申请号：EP99941999.7
申请日：1999-08-04
Applicant: COR THERAPEUTICS, INC.
Inventor： RAMAKRISHNAN, Vanitha , PHILLIPS, David, R.
IPC: C12N15/00 , A01K67/027 , C12N15/12 , C07K14/705 , C12N5/10 , A61K49/00
CPC classification number: C12N15/8509 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0381 , C07K14/705
Abstract: The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therapeutic agents.
-
公开(公告)号：EP0422125B1
公开(公告)日：1996-10-23
申请号：EP89908344.8
申请日：1989-06-30
Applicant: COR THERAPEUTICS, INC.
Inventor： CHARO, Israel, F. , FITZGERALD, Laurence, A. , PHILLIPS, David, R.
CPC classification number: C07K14/70557 , A61K38/00 , C07K2319/00 , C07K2319/33 , Y10S530/806
Abstract: Methods and compositions are provided for treating platelet-associated ischemic syndromes utilizing oligopeptides corresponding to regions of the platelet GPIIIa protein. The oligopeptides can be used to block platelet aggregation for numerous applications, and can serve in immunogen to raise receptor-specific antibodies.
-
公开(公告)号：EP0707648A1
公开(公告)日：1996-04-24
申请号：EP94923370.0
申请日：1994-07-07
Applicant: COR THERAPEUTICS, INC.
Inventor： LANZA, François , PHILLIPS, David, R. , CAZENAVE, Jean-Pierre
CPC classification number: C07K14/705 , A61K38/00
Abstract: This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with other glycoproteins is described and several uses of the isolated glycoprotein v gene are shown.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.025 seconds)
